Late Quaternary Intraplate Deformation Defined by the Las Chacras Fault Zone, West‐Central Argentina

Several major (up to MW 7.5) earthquakes over the past 320 years have shaken the thick-skinned Sierras Pampeanas region of Argentina, despite exhibiting much lower GPS-shortening rates than across the thin-skinned Precordillera region to its west. Whether geodetic shortening rates indicate an actual long-term shortening gradient, and whether shortening rates translate to higher uplift rates due to steeper faults in the Sierras Pampeanas, remain uncertain due to the limited spatio-temporal coverage and the inherently large error in the vertical component of deformation of GPS measurements. We measure geomorphic offsets and use 10Be terrestrial cosmogenic nuclide surface exposure dating to determine slip rates on the Las Chacras Fault Zone (LCFZ)—an ∼30 km long, NNW-trending, steeply dipping (55–65°E) reverse fault that branches off of the longest, westernmost, thick-skinned Valle Fértil range-front fault in the western Sierras Pampeanas. Average shortening and uplift rates measured on the LCFZ are ∼0.2 and ∼0.3–0.4 mm/yr, respectively. Despite an uplift rate similar to most other faults in the region, the LCFZ shortening rate is lower than faults to its west; this is in agreement with the inferred west-east decrease in shortening rates from GPS data, indicating consistent regional deformation patterns since the Late Pleistocene. The decrease in shortening to the east coincides spatially with the termination of the flat portion of the subducted Nazca plate between 67 and 68°W. From scaling relationships among magnitude, slip rate, and fault length, the LCFZ is capable of generating earthquakes of MW 6.7–7.1.Fil: Rimando, Jeremy. University of Toronto; CanadáFil: Schoenbohm, Lindsay. University of Toronto; CanadáFil: Ortiz, Gustavo Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan. Centro de Investigaciones de la Geosfera y Biosfera. Universidad Nacional de San Juan. Facultad de Ciencias Exactas Físicas y Naturales. Centro de Investigaciones de la Geosfera y Biosfera; Argentina. Universidad Nacional de San Juan. Facultad de Ciencias Exactas, Físicas y Naturales. Departamento de Geofísica y Astronomía; ArgentinaFil: Alvarado, Patricia Monica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan. Centro de Investigaciones de la Geosfera y Biosfera. Universidad Nacional de San Juan. Facultad de Ciencias Exactas Físicas y Naturales. Centro de Investigaciones de la Geosfera y Biosfera; Argentina. Universidad Nacional de San Juan. Facultad de Ciencias Exactas, Físicas y Naturales. Departamento de Geofísica y Astronomía; ArgentinaFil: Venerdini, Agostina Lia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan. Centro de Investigaciones de la Geosfera y Biosfera. Universidad Nacional de San Juan. Facultad de Ciencias Exactas Físicas y Naturales. Centro de Investigaciones de la Geosfera y Biosfera; Argentina. Universidad Nacional de San Juan. Facultad de Ciencias Exactas, Físicas y Naturales. Departamento de Geofísica y Astronomía; ArgentinaFil: Owen, Lewis. North Carolina State University; Estados UnidosFil: Seagren, Erin. University of Toronto; CanadáFil: Marques Figueiredo, Paula. North Carolina State University; Estados UnidosFil: Hammer, Sarah. University of Cincinnati; Estados Unido

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients <65 years of age, with good prognosis (136 per arm) were randomized (1:1) to receive six cycles of either RTXM83 or R-rituximab. The primary efficacy endpoint was achieved (overall response rate of 83.6% for RTXM83 and 82.9% for R-rituximab) with a difference 0.7% between arms (95%CI: [-8.77% to 10.17%]) fulfilling the predefined non-inferiority margin (-13%). Similar number of patients reported at least one adverse event (AE) (131 per arm) or one serious AE (47 with RTXM83 and 45 with R-rituximab). Anti-drug antibody development was comparable between the arms. PK/PD secondary endpoint results support similarity between the compounds. RTXM83 exhibits non-inferior efficacy and similar safety/immunogenicity to R-rituximab, being an accessible alternative for the treatment of patients with previously untreated DLBCL